Loading clinical trials...
Loading clinical trials...
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity
Conditions
Interventions
NNC0174-0833
Semaglutide
+1 more
Locations
1
United States
Novo Nordisk Investigational Site
Overland Park, Kansas, United States
Start Date
July 25, 2018
Primary Completion Date
June 12, 2020
Completion Date
June 12, 2020
Last Updated
November 17, 2021
NCT07472881
NCT01143454
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions